International Strategies for Tropical Disease Treatments - Experiences with Praziquantel - EDM Research Series No. 026
(1998; 113 pages) View the PDF document
Table of Contents
View the documentAbstract
View the documentAcknowledgments
View the documentInformation on authors
View the documentExchange rates used in the report
Open this folder and view contentsChapter 1: Policies for praziquantel*
Open this folder and view contentsChapter 2: Bayer & E. Merck: Discovery and development of praziquantel*
Open this folder and view contentsChapter 3: Shin Poong Pharmaceutical Co.: Process development in the Republic of Korea*
Open this folder and view contentsChapter 4: The Egyptian International Pharmaceutical Industries Co.: Praziquantel formulation*
Close this folderChapter 5: The international supply of praziquantel*
View the documentProducers and formulators
View the documentGlobal distribution of praziquantel
View the documentReferences
Open this folder and view contentsChapter 6: Demand for praziquantel and national distribution*
Open this folder and view contentsChapter 7: Prices and production costs of praziquantel*
View the documentOther documents in the DAP Research Series
View the documentDAP Research Series No. 26
 

Chapter 5: The international supply of praziquantel*

* By Ramesh Govindaraj, Michael R. Reich, and Karin Dumbaugh.

This chapter provides a description of the supply of praziquantel since its introduction in the international market in the late 1970s. It first presents basic data on producers and formulators of praziquantel, including firms that manufacture the drug’s active ingredients and firms that only formulate tablets from purchased raw materials. The chapter next describes the global distribution of praziquantel, with particular attention to the role of bulk suppliers in developing country markets.

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: June 25, 2014